ClinicalTrials.gg
CompletedNCT01561352Updated Jan 12, 2017

Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis

A Phase 2 interventional study of activated recombinant human factor VII in Other Haemostasis Disorder and Haemorrhagic Cystitis, sponsored by Novo Nordisk A/S. Completed at 3 sites in United States. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-01-12.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Non-randomized
Ages
2 Years to 65 Years
Sex
All
01

Study summary

This trial is conducted in the United States of America (USA). The aim of this trial is to assess the efficacy of activated recombinant human factor VII in the treatment of refractory haemorrhagic cystitis (HC) following chemotherapy.

02

Conditions studied

  • Other Haemostasis Disorder
  • Haemorrhagic Cystitis
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Severe haemorrhagic cystitis (HC)

Exclusion criteria

Exclusion Criteria:

  • Patients with overt DIC (disseminated intravascular coagulation)
  • Patients with known active atherosclerotic disease, such as active coronary artery disease or recent stroke in the past 3 months
  • Central venous access device related thrombus in the last 3 months
  • Patients with allergy to activated recombinant human factor VII or any component of its preparation
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Factor VII

    Drug: activated recombinant human factor VII

Interventions

  • If non-responding haemorrhagic cystitis to 24-hour trial of conventional therapy, 80 mcg/kg is administered i.v. for the first dose. If necessary, two additional doses of 120 mcg/kg can be administered i.v.

06

What researchers measure

Primary outcomes

  1. Reduction of hematuria that failed 24-hour standard therapy evaluated by change of urine color

  2. Reduction of hematuria that failed 24-hour standard therapy evaluated by urine haemoglobin content

  3. Reduction of hematuria that failed 24-hour standard therapy evaluated by urocrit

Secondary outcomes

  1. Symptoms of venous or arterial thrombosis

07

Study locations

3 sites
  • Novo Nordisk Investigational Site
    Chapel Hill, North Carolina 27599-7035, United States
  • Novo Nordisk Investigational Site
    Chapel Hill, North Carolina 27599-7400, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77030-4009, United States
08

References and documents

Publications

  • Ashrani AA, Gabriel DA, Gajewski JL, Jacobs DR Jr, Weisdorf DJ, Key NS. Pilot study to test the efficacy and safety of activated recombinant factor VII (NovoSeven) in the treatment of refractory hemorrhagic cystitis following high-dose chemotherapy. Bone Marrow Transplant. 2006 Dec;38(12):825-8. doi: 10.1038/sj.bmt.1705535. No abstract available. PubMed 17133240 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2001, a primary completion of Nov 2003 and a completion of Nov 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2012
First posted
Mar 23, 2012
Start
Sep 2001
Primary completionActual
Nov 2003
CompletionActual
Nov 2003
Last update
Jan 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01561352
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 23, 2012
Start date
Sep 2001
Primary completion
Nov 2003
Completion
Nov 2003
Last update
Jan 12, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion